** U.S.-listed shares of Canadian cannabis firm Tilray Brands TLRY.O up 8.9% at $9.95 premarket

** Co posts Q2 net revenue of $217.5 mln, up 3% from $211 mln a year earlier and in line with analyst estimates of $217.51 mln - data compiled by LSEG

** Adj. net loss narrows to $1.9 mln vs. $2.2 mln a year earlier

** TLRY sees U.S. federal rescheduling as key for medical cannabis; plans to leverage $150 mln global medical cannabis business and $300 mln pharma platform for expansion

** As of last close, TLRY stock down 33.3% over the past year

(Reporting by Tharuniyaa Lakshmi in Bengaluru)

((tharuniyaa@thomsonreuters.com))